Please login to the form below
Advent
This page shows the latest Advent news and features for those working in and with pharma, biotech and healthcare.
Pfizer’s flat sales focus investor attention on M&A
In the last few weeks Sanofi has sold its European generics business to Advent, GlaxoSmithKline divested its rare disease unit to start-up Orchard Therapeutics after buying Novartis out of a
Latest news
-
P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit
In the last few weeks Sanofi has sold its European generics business to Advent, GlaxoSmithKline divested its rare disease unit to start-up Orchard Therapeutics after buying Novartis out of a
-
Sanofi sells European generics to Advent for $2.4bn
Sanofi sells European generics to Advent for $2.4bn. The deal will create a new, independent European generics company. ... Private equity group Advent has agreed a 1.9bn ($2.4bn) deal to buy the European generics unit of French pharma company Sanofi.
-
Time running out on new Stada takeover bid
That offer beat out a rival overture from Advent and Permira.
-
Trouble at the top of Stada as Bain and Cinven mull fresh bid
Their offer beat out another bid from Advent and Permira.
-
No deal for Stada as private equity takeover bid collapses
Stada's board had lent its support to the Bain-Cinven offer over a rival 58 per share bid from Advent and Permira.
More from news
Approximately 3 fully matching, plus 97 partially matching documents found.
Latest Intelligence
-
Cancer care – the power of new technologies
Generally, new medicines and treatment approaches are offering renewed hope for cancer patients and the advent of innovative digital technologies is starting to disrupt clinical practice, presenting new ways of driving
-
Reaching the new influencers
Right now, we’re living through healthcare’s age of accelerations - as evidenced by advances in everything from biotechnology and stem cell research to machine learning and the advent (and approvals)
-
Cancer in The Information Age: are we illuminated or inundated?
Personalised vs personal medicine. Data and information have already proved fruitful in the clinic, yielding the advent of personalised cancer medicine,.
-
No incentive for a cure
the health of motor neurons. The advent of these ‘regenerative medicines’ - often highly tailored to the patient’s specific genetic make-up - is a genuine revolution in healthcare.
-
Brexit Means Brexit
This will have significant downstream implications.”. Clearly, pharmaceutical regulation has always been a dynamic and complex landscape - but the advent of Brexit brings additional layers of complexity and uncertainty that are
More from intelligence
Approximately 0 fully matching, plus 28 partially matching documents found.
Latest from PMHub
-
SWITCHED ONcology Patient Experience Focus Group Full Discussion
The focus group provided deeper insight in to a number of themes including the transformation of cancer understanding, the barriers to cancer diagnosis, the advent of new treatments including immunotherapy, communication
-
Training the next generation of biotech leaders
With the advent of personalised medicine, biotechs and academia are focusing their efforts on ensuring the manufacturing process can be both scaled up and reproduced.
-
Marketing strategy in complex environments
One example of this is in cystic fibrosis, and the advent of disease modifying agents specific towards certain genetic mutations (With multiple product launches on the horizon, it is anticipated that
-
Data Visualisation in Medical Communication
The advent of big data means that we now have access to unprecedented volumes of data, but we need tools to process and understand it.
-
The changing role of the expert in healthcare: challenges in customer-centricity
However, the advent of the internet has provided an easily accessible way for patients to become better informed about their condition and treatment options.
More from PMHub
Approximately 0 fully matching, plus 12 partially matching documents found.
Featured jobs
- Director Healthcare PR Communications
-
Salary TBC
-
Associate Medical Director
-
Salary TBC
- Account Manager, Healthcare Advertising
-
Salary TBC
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 benefits
- Account Director – Global Healthcare PR
-
Salary TBC
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
-
Associate Medical Director
-
Highly Competitive
- Senior Account Manager / Account Director - Med Comms
-
Great salary and benefits
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Lead Medical Copywriter, Healthcare Brand Communications, London
-
Excellent package
-
Account Director - Digital
-
Great salary and benefits
-
Senior Account Manager - Med Comms
-
Highly Competitive Salary &Benefits
-
Scientific Director
-
Highly Competitive Salary &Benefits
- Experienced Editor, London, Medical Communications
-
Competitive package
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
-
Account Director
-
Negotiable
-
Scientific Team Lead
-
Competitive Salary
Subscribe to our email news alerts
- Shire’s angioedema drug Takhzyro recommended in Europe
- Cuttsy+Cuttsy launch their latest patient e-book
- McCann Health London launch Urban Eye Test
- Encouraging data for GenSight’s blinding retinal disease gene therapy
- Keytruda hits survival targets in first-line kidney cancer
- UK ‘unicorn’ Oxford Nanopore bags $65m backing from Amgen
PMHub
90TEN Healthcare
90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...
Latest intelligence
- Retaining reader value in plain language summaries of clinical studies
- Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
- Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
- Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
- Making Europe a leader in bioscience: boosting trust and opening minds
- A vision of Paris as Europe's leading hub for life sciences innovation...
Quick links
Infographics
